CN119816318A - 鼻内施用的用于治疗感觉神经性耳聋的bdnf - Google Patents

鼻内施用的用于治疗感觉神经性耳聋的bdnf Download PDF

Info

Publication number
CN119816318A
CN119816318A CN202380063429.2A CN202380063429A CN119816318A CN 119816318 A CN119816318 A CN 119816318A CN 202380063429 A CN202380063429 A CN 202380063429A CN 119816318 A CN119816318 A CN 119816318A
Authority
CN
China
Prior art keywords
bdnf
concentration
hearing loss
use according
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380063429.2A
Other languages
English (en)
Chinese (zh)
Inventor
安娜·丽塔·费托尼
安德烈亚·阿拉米尼
劳拉·布兰多利尼
帕斯夸莱·科基亚罗
蒂齐亚纳·罗密欧
尼古拉·代塔
露西娅·阿帕伦特
西蒙娜·马蒂奥利
弗兰卡·卡塔尼
弗拉维奥·曼泰利
马尔塞洛·阿莱格雷蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dompe Farmaceutici SpA
Original Assignee
Dompe Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Farmaceutici SpA filed Critical Dompe Farmaceutici SpA
Publication of CN119816318A publication Critical patent/CN119816318A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN202380063429.2A 2022-08-05 2023-08-04 鼻内施用的用于治疗感觉神经性耳聋的bdnf Pending CN119816318A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22189067.6 2022-08-05
EP22189067.6A EP4316462A1 (en) 2022-08-05 2022-08-05 Intranasal administration of bdnf for the treatment of sensorineural hearing loss
PCT/EP2023/071676 WO2024028483A1 (en) 2022-08-05 2023-08-04 Intranasal administration of bdnf for the treatment of sensorineural hearing loss

Publications (1)

Publication Number Publication Date
CN119816318A true CN119816318A (zh) 2025-04-11

Family

ID=83080998

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380063429.2A Pending CN119816318A (zh) 2022-08-05 2023-08-04 鼻内施用的用于治疗感觉神经性耳聋的bdnf

Country Status (8)

Country Link
US (1) US20260048006A1 (https=)
EP (2) EP4316462A1 (https=)
JP (1) JP2025525990A (https=)
CN (1) CN119816318A (https=)
AU (1) AU2023317860A1 (https=)
CA (1) CA3263977A1 (https=)
IL (1) IL318653A (https=)
WO (1) WO2024028483A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4623926A1 (en) * 2024-03-26 2025-10-01 Dompe' Farmaceutici SpA Intranasal administration of bdnf for treatment of primary headaches

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2278999B1 (en) * 2008-04-21 2025-01-29 Dompé farmaceutici S.p.A. Auris formulations for treating otic diseases and conditions
WO2019140012A1 (en) * 2018-01-09 2019-07-18 Otonomy, Inc. Growth factor otic formulations
WO2021030452A1 (en) * 2019-08-14 2021-02-18 Decibel Therapeutics, Inc. Permeation enhancers, compositions containing them, and methods of using the same
WO2021151013A1 (en) * 2020-01-24 2021-07-29 Otonomy, Inc. Growth factor formulation for condition associated with otic event
US20240066099A1 (en) * 2020-12-15 2024-02-29 Dompé Farmaceutici S.P.A. Bdnf otic formulations and use thereof

Also Published As

Publication number Publication date
WO2024028483A1 (en) 2024-02-08
EP4565254A1 (en) 2025-06-11
US20260048006A1 (en) 2026-02-19
AU2023317860A1 (en) 2025-02-13
EP4316462A1 (en) 2024-02-07
CA3263977A1 (en) 2024-02-08
JP2025525990A (ja) 2025-08-07
IL318653A (en) 2025-03-01

Similar Documents

Publication Publication Date Title
US10632147B2 (en) Methods and compositions for treating inflammatory disorders
Noushi et al. Delivery of neurotrophin-3 to the cochlea using alginate beads
Meyerhoff et al. Tympanostomy tubes and otic drops
Eby et al. Ineffectiveness of zinc gluconate nasal spray and zinc orotate lozenges in common-cold treatment: a double-blind, placebo-controlled clinical trial
JP2009510047A (ja) 蝸牛興奮毒性によって誘導される耳鳴りを処置する方法
MXPA06011078A (es) Uso de un antagonista del receptor nmda para el tratamiento de tinito inducido por excitotoxicidad coclear.
O'Day et al. Influence of corticosteroid on experimentally induced keratomycosis
JP2001522807A (ja) バソプレシンアンタゴニストの使用
US20210393680A1 (en) Use of an antimicrobial composition
CN119816318A (zh) 鼻内施用的用于治疗感觉神经性耳聋的bdnf
EP2734209B1 (en) Intranasal administration of agents with pro-inflammatory activity for the therapy of neurological disorders
CN119836297A (zh) 鼻内施用的用于治疗感觉神经性耳聋的ngf
Jiang et al. Eyedrop delivery of therapeutic proteins with zwitterionic polymers to treat dry age-related macular degeneration
Algvere et al. Panretinal photocoagulation aggravates experimental proliferative vitreoretinopathy
JP6601882B2 (ja) 感音性難聴の治療用のステロール誘導体の利用及び対応する組成物
CN108310386A (zh) mTOR信号通路抑制剂在制备预防或治疗非遗传性听力障碍药物中的用途
CN113230390A (zh) 一种组合物、阴道洗剂及其在妇科黏膜损伤修复中的应用
US7390482B2 (en) Drug for auditory dysfunction
US12390510B2 (en) Methods of treating sensorineural hearing loss using fibroblast growth factor 2 (FGF2)
RU2816583C1 (ru) Применение пептида формулы met-glu-his-phe-pro-gly-pro для лечения аносмии при covid-19
Melén et al. Ostial function in allergic rhinitis
Coez et al. Arterial spin labeling brain MRI (ASL-MRI) study to evaluate the impact of deafness on cerebral perfusion in 79 children before cochlear implantation.
El Gandy et al. Jacobs Journal of Otolaryngology
Nguyen et al. Atraumatic cochlear implant insertion with the robotassistance of RobOtol®.
EP4568689A1 (en) Compositions and use in methods for treating a cognitive deficit

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination